Operator: Thank you. Our next question comes from Jason Gerberry of Bank of America. Your line is open.
Jason Gerberry: Hey, guys. Thanks for taking my question. My question pertains to your sales guidance for 2023. It looks pretty conservative, especially in the context of Vision 2025, which ex-corp development, I think is $4.5 billion, which would imply like basically off your 2023 midpoint, you have to gain $350 million in sales in ’24 and ’25, respectively. But you’re only modeling about plus $100 million in revs in 2023. So, just wondering if you could shed a little bit more light on that dynamic, that’d be helpful. Thanks.
Bruce Cozadd: Yes. Thanks, Jason. I’ll start and then invite Renee to jump in. What you’re seeing in ’23 and I think Renee did a nice job of this in laying out the guidance is real growth in all of our core products, offset by continuing significant decline in Xyrem. And I just think as you get out to later years, you’re going to continue to see growth in our key products, but you’ve already suffered a lot of the loss in Xyrem and so the net gain becomes a little clear. And I think one of the rationales of rolling out Vision 2025 to give people a little more context to the growth curve over time was to make sure people understood that we would be going through this transition in 2023.
Renee Gala: So, maybe just to build on that further, Bruce. So, as Bruce described, we had — we have these multiple dynamics at play, right? We have this dynamic of growth within Xywav, Epidiolex, Rylaze and Zepzelca, but that is offset by the continued decline in Xyrem. In large part due to the strong uptake of Xywav, but also through the introduction of AG, which, of course, we earn royalties on. And then, as we move forward, we also expect, as Bruce has mentioned, to see continued growth in ’24 and ’25. So, what does it mean based on our ’23 guidance, which does have more muted growth on a consolidated basis based on the dynamics that we’ve shared here today, what does it mean in terms of ’24 and ’25? Well, that means you’re delivering low-double-digit growth from your existing business and continuing to be active on the BD front, which we expect to be.
And we’ve also stated that we do expect zani to contribute to our 2025 revenue. We also expect we’ll need to continue to be active as we have done over the last several years, each year closing a transaction that has resulted quite quickly in revenue generation. So, that’s how we’re thinking about the overall guidance and feeling good about where we are.
Operator: Thank you. Our next question comes from Annabel Samimy with Stifel. Your line is open.
Annabel Samimy: Hi. Thanks for taking my question. I’m going to be different and ask something about your new product, this pipeline product, zani. So, regarding the Phase 2 open-label data in first-line GEA in combination with chemo, I guess, could you put this into context with the current Phase 3 data that — or Phase 2 trial that’s ongoing? And how comfortable are you that — I guess, some of this data can be indicative of potential success in the Phase 3 study. How similar are the different arms? And is there something that can draw from it, or is the population too small at this point? And when might we be able to see this data? And then, just as a quick follow on, you clearly have a number, a tremendous number of opportunities here with anti-HER2 agent. How will you be making the decisions on the new tumor types? And when might we be able to hear about some of these programs that you’re going to be moving forward? What gets you excited? Thanks.
